Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory / Edition 1

by Alan H. B. Wu, Kiang-Teck J. Yeo

Overview

While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.

Product Details

ISBN-13:	9781617797262
Publisher:	Springer-Verlag New York, LLC
Publication date:	04/19/2013
Series:	Molecular and Translational Medicine
Edition description:	2011
Pages:	272
Product dimensions:	6.10(w) x 9.25(h) x 0.04(d)

Table of Contents

Part 1.        Basic concepts      

Chapter 1.      Issues in Translation of Pharmacogenomics into Clinical Practice.

                        Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu

Chapter 2.      Molecular Diagnostic Methods in Pharmacogenomics

                        Nikolina Babic^*, Loren J. Joseph, Kiang-Teck J. Yeo

Chapter 3.      Economics of pharmacogenomic testing in clinical practice

                        Alan H.B. Wu

Chapter 4.      From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

Part 2.        Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5.      Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6.      Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7.      Thiopurines

Terreia S. Jones, Mary V. Relling

Part 3.       Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8.      The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9.      Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10.    DNA-Guided Statin Therapy

Gualberto Ruaño, Richard L. Seip, Jorge Duconge

Chapter 11.    The statin response gene: Kif6

....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.

Part 4.        Drugs that cause delayed hypersensitivity

Chapter 12.    Abacavir

Elizabeth J. Phillips, Simon A. Mallal

Chapter 13.    Allopurinol

Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen

Chapter 14.   Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

Part 2.        Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5.      Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6.      Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7.      Thiopurines

Terreia S. Jones, Mary V. Relling

Part 3.        Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8.      The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9.      Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10.    DNA-Guided Statin Therapy

Gualberto Ruaño, Richard L. Seip, Jorge Duconge

Chapter 11.    The statin response gene: Kif6

....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.

Part 4.        Drugs that cause delayed hypersensitivity

Chapter12.    Abacavir

Elizabeth J. Phillips, Simon A. Mallal

Chapter 13.    Allopurinol

Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen

Chapter 14.   Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Chapter 14.   Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Editorial Reviews

Reviewer: Valerie L Ng, PhD MD(Alameda County Medical Center/Highland Hospital)
Description: The title — Pharmacogenomic Testing in Current Clinical Practice — exactly describes the content of this book.
Purpose: The purpose is to provide a compilation of pharmacogenomic tests in current clinical use. These are very worthy objectives for this rapidly evolving discipline.
Audience: The book is written for clinical laboratory directors "contemplating or assigned the task of establishing a pharmacogenomics laboratory," pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to clinical laboratory scientists (in practice or training), pathologists, or laboratory medicine practitioners (in training or in practice), interested allied health practitioners, regulators, reimbursers, and test device manufacturers. The authors are well established authorities in this field.
Features: The four parts of the book cover basic concepts, chemotherapeutics, cardiovascular drugs, drugs causing delayed hypersensitivity and miscellaneous drugs. Aside from the basic concept chapters, the rest follow the same forma, progressing from an introduction to pharmacology, pharmacogenomics, dosing algorithms, and clinical utility. Many finish with an illustrative case study deftly weaving together the salient points. The writing is concise, clear, and accessible for what might be considered a complex topic. I found the writing so engaging that I read many chapters at one sitting. What I really like about this book is the open and honest discussion about clinical utility, i.e., the clinical promise not yet accepted into routine clinical use. The chapter on vitamin K antagonist anticoagulation was especially illuminating on the tension between the FDA approving inclusion of pharmacogenomic testing on drug labeling but the CMS rationale for not authorizing reimbursement. I also liked the chapter on personalized medicine and personalized justice — a topic with which I was completely unfamiliar. My only lament, shared by the editors up front, is that this book is representative of today and the field will likely change quickly. I guess the bright side of this lament is we have multiple future editions to keep us up to date.
Assessment: Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing.

Doody's Review Service

From the reviews:

“The book is written for clinical laboratory directors ‘contemplating or assigned the task of establishing a pharmacogenomics laboratory,’ pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to … allied health practitioners, regulators, reimbursers, and test device manufacturers. … The writing is concise, clear, and accessible for what might be considered a complex topic. … Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing.” (Valerie L. Ng, Doody’s Review Service, May, 2011)

From the Publisher